ArticleBlood2018

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.

Tycel J Phillips et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.